此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

A Phase IIa Multicenter, Randomized, Double-blind, Double-dummy, and Placebo- and Active Controlled Study to Investigate the Safety and Efficacy of JNJ-18038683 Administered to Subjects With Major Depressive Disorder

The purpose of this study is to evaluate the safety and effectiveness of JNJ-18038683 compared to escitalopram and placebo in patients with moderate to severe depression.

研究概览

详细说明

This study is being done to assess safety and tolerability and to explore the effectiveness of a new, experimental drug in the treatment of moderate to severe depression. Approximately 225 patients with depression will be recruited for the study. Patients who meet study criteria will need to stop taking any depression medications they are currently using. They will be randomly assigned to one of 3 treatment arms; each patient has an equal chance of receiving 20 mg JNJ-18038683, 20 mg escitalopram, or placebo. Placebo has no active drug. Escitalopram is a drug currently approved to treat depression. This is a blinded study, ie the patient, the study doctor, and the study sponsor will not know what treatment the patient receives until all patients complete the study. Patients receiving either escitalopram or JNJ-18038683 will be titrated up to their assigned dose, receiving 10 mg doses for one week prior to increasing to 20 mg. Patients who are not able to tolerate 20 mg of JNJ-18038683 will be allowed to drop down to the 10 mg dose at any time after the titration period. Patients taking 20 mg escitalopram will receive 10 mg at their final week to taper off of the drug. Patients will receive a drug blister card at each weekly visit containing drug for the upcoming week. The study doctor and the sponsor will monitor the study for the occurrence of possible side effects. In addition to a screening visit, patients will return weekly for 9 additional study visits. After completing the study, patients may resume other depression medications. Medical and psychiatric history, physical examination, blood pressure, heart rate, temperature, weight and electrocardiograms (ECGs) will be checked periodically. Blood samples will be taken for standard safety laboratory tests as well as for the measurement of the drug blood level. Questionnaires relating to depression, sleep and sexual experience will be administered throughout the study. Each day for nine weeks, patients will take orally two JNJ-18038683 tablets, active and/or placebo, and two escitalopram capsules, active and/or placebo.

研究类型

介入性

注册 (实际的)

67

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Arkansas
      • Little Rock、Arkansas、美国
    • California
      • Beverly Hills、California、美国
      • Glendale、California、美国
      • San Diego、California、美国
    • Florida
      • Bradenton、Florida、美国
      • Maitland、Florida、美国
      • Orlando、Florida、美国
    • Georgia
      • Atlanta、Georgia、美国
    • Idaho
      • Eagle、Idaho、美国
    • Illinois
      • Chicago、Illinois、美国
    • Kansas
      • Prairie Village、Kansas、美国
      • Topeka、Kansas、美国
    • Louisiana
      • Baton Rouge、Louisiana、美国
      • Shreveport、Louisiana、美国
    • New Jersey
      • Nutley、New Jersey、美国
    • New York
      • Brooklyn、New York、美国
      • Cedarhurst、New York、美国
      • Fresh Meadows、New York、美国
    • Ohio
      • Cincinnati、Ohio、美国
    • Oklahoma
      • Oklahoma City、Oklahoma、美国
    • Oregon
      • Portland、Oregon、美国
    • Pennsylvania
      • Norristown、Pennsylvania、美国
    • Tennessee
      • Memphis、Tennessee、美国
    • Texas
      • Austin、Texas、美国
      • Irving、Texas、美国
    • Virginia
      • Richmond、Virginia、美国

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 60年 (成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Diagnosed with moderate to severe major depressive disorder
  • Willing to use acceptable methods of birth control throughout the study and for 3 months after
  • In good general health

Exclusion Criteria:

  • No history or current diagnosis of other psychiatric conditions such as bipolar disorder, psychotic disorder, general anxiety disorder, anorexia, obsessive compulsive disorder, post traumatic stress disorder, antisocial personality disorder, mental retardation, pervasive developmental disorder, or cognitive disorder
  • No history or presence of drug abuse
  • No use of prescription medications or herbal medications other than hormone replacement therapies
  • No prior history of heart disease or current significant blood, lung, kidney, liver, heart, breathing, neurologic or thyroid disorders
  • No patients who are either pregnant or nursing

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:安慰剂
Form= capsule, route= oral use. Administration once daily for 8 weeks.
Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week.
有源比较器:艾司西酞普兰
Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 20 mg daily for 6 weeks, and 10 mg daily for 1 week.
实验性的:JNJ-18038683
Form= capsule, route= oral use. Administration once daily for 8 weeks.
Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Explore the effectiveness of JNJ-18038683 in patients with moderate to severe depression as determined by accepted clinical assessments done throughout the study.
大体时间:Clinical assessments to evaluate depression will be done 8 times at weekly visits from baseline through the Week 7 visit.
Clinical assessments to evaluate depression will be done 8 times at weekly visits from baseline through the Week 7 visit.

次要结果测量

结果测量
大体时间
Explore the safety and tolerability of JNJ-18038683 in patients with moderate to severe depression by assessing adverse events, vital signs, laboratory test results, ECGs and physical exams.
大体时间:Vital signs will be collected weekly throughout the study; ECGs will be collected at screening, baseline, Wks 3 and 7; Laboratory test will be collected at screening, baseline, and Wks 1,3,5,7 and 8. Adverse Events will be throughout the study.
Vital signs will be collected weekly throughout the study; ECGs will be collected at screening, baseline, Wks 3 and 7; Laboratory test will be collected at screening, baseline, and Wks 1,3,5,7 and 8. Adverse Events will be throughout the study.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Clinical Trial、Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2007年12月1日

初级完成 (实际的)

2008年12月1日

研究完成 (实际的)

2008年12月1日

研究注册日期

首次提交

2007年11月29日

首先提交符合 QC 标准的

2007年11月29日

首次发布 (估计)

2007年12月3日

研究记录更新

最后更新发布 (估计)

2014年8月6日

上次提交的符合 QC 标准的更新

2014年8月1日

最后验证

2014年8月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅